Vaccines save lives by protecting people against infectious diseases — polio, influenza, and pneumonia to name a few. Kaiser Permanente Washington Health Research Institute (KPWHRI) is working to protect communities through research to continually improve the safety and effectiveness of vaccines for infectious diseases of public health importance.
Central to this work is testing new vaccines against emerging diseases — such as COVID-19. In March 2020, KPWHRI gave the world’s first-ever injection of an investigational vaccine for COVID-19 in a phase 1 clinical trial led by Senior Investigator Lisa A. Jackson, MD, MPH. We continue to be at the forefront of efforts to understand and combat COVID-19. To learn more, see COVID-19 research at KPWHRI.
Successes over 3 decades of KPWHRI vaccine research include:
Our current research projects on vaccines and infectious diseases include:
Keitel WA, Jackson LA, Edupuganti S, Winokur PL, Mulligan MJ, Thornburg NJ, Patel SM, Rouphael NG, Lai L, Bangaru S, McNeal MM, Bellamy AR, Hill HR. Safety and immunogenicity of a subvirion monovalent unadjuvanted inactivated influenza A/H3N2 variant (H3N2V) vaccine in healthy persons>/=18 years old. J Infect Dis. 2015 Feb 3. pii: jiv056 [Epub ahead of print]. PubMed
Keitel WA, Jackson LA, Edupuganti S, Winokur PL, Mulligan MJ, Thornburg NJ, Patel SM, Rouphael NG, Lai L, Bangaru S, McNeal MM, Bellamy AR, Hill HR; VTEU H3N2v Vaccine Study Work Group. Safety and immunogenicity of a subvirion monovalent unadjuvanted inactivated influenza A(H3N2) variant vaccine in healthy persons =18 years old. J Infect Dis. 2015 Aug 15;212(4):552-61. doi: 10.1093/infdis/jiv056. Epub 2015 Feb 3.
Kelly BJ, Leader AE, Henrikson NB. Editorial: Promising strategies for vaccine messages: the message and the source. Front Public Health. 2022 Aug 31;10:971283. doi: 10.3389/fpubh.2022.971283. eCollection 2022. PubMed
Kenigsberg TA, Goddard K, Hanson KE, Lewis N, Klein N, Irving SA, Naleway AL, Crane B, Kauffman TL, Xu S, Daley MF, Hurley LP, Kaiser R, Jackson LA, Jazwa A, Weintraub ES. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. Vaccine. 2023 Sep 7;41(39):5678-5682. doi: 10.1016/j.vaccine.2023.08.023. Epub 2023 Aug 19. PubMed
Kenigsberg TA, Hanson KE, Klein NP, Zerbo O, Goddard K, Xu S, Yih WK, Irving SA, Hurley LP, Glanz JM, Kaiser R, Jackson LA, Weintraub ES. Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink. Vaccine. 2023 Jun 15:S0264-410X(23)00717-X. doi: 10.1016/j.vaccine.2023.06.042. [Epub ahead of print]. PubMed
Lisa A. Jackson, MD, MPHSenior Investigator |
Jennifer C. Nelson, PhDDirector, Biostatistics; Senior Investigator |
Andrea J. Cook, PhDSenior Biostatistics Investigator |
Sascha Dublin, MD, PhDSenior Investigator |
Onchee Yu, MSPrincipal Collaborative Biostatistician |
Robert D. Wellman, MSPrincipal Collaborative Biostatistician |
Clarissa Hsu, PhDAssociate Investigator |
Brian D. Williamson, PhDAssistant Biostatistics Investigator |
Noorie Hyun, PhDAssociate Biostatistics Investigator |
Pamela A. Shaw, PhD, MSSenior Biostatistics Investigator |
Annie Piccorelli, PhDSenior Collaborative Biostatistician |
Doug Opel, MD, MPH
University of Washington (UW) Department of Bioethics and Humanities; UW Department of Pediatrics; UW Medical Center
John Dunn, MD, MPH
Kaiser Foundation Health Plan of Washington
Elizabeth Lin, MD, MPH
Kaiser Foundation Health Plan of Washington Family Practice;
Kaiser Permanente Washington Health Research Institute